White House Credits Eli Lilly With Help In Final Deal On Patent Reform Bill
This article was originally published in The Pink Sheet Daily
At President Obama's urging the CEOs of Lilly and Cisco met with Commerce Department officials to hammer out their differences to get the legislation through Congress.
You may also be interested in...
Parallel district court litigation would no longer be factor in deciding whether to institute PTAB review of patents under Senate bill. BIO favors PTO discretion, would like claim amendments to be addressed.
Biopharma and generic industries stand on opposing sides in case that could eliminate the patent challenge proceeding. Interactive timeline covers IPR's five-year history leading to oral arguments Nov. 27.
Genzyme’s Myozyme patents invalid for being obvious, Patent Trial and Appeal Board finds in inter partes review.